Polymorphisms in the Tumor Necrosis Factor Receptor Genes Affect the Expression Levels of Membrane-Bound Type I and Type II Receptors

Figure 4

(a) Number of membrane-bound TNFRI present on CD19⁺ cells in individuals presenting with different genotypes combinations of SNPs TNFRI −609G/T (rs4149569) and TNFRII −3609C/T (rs590368). Kruskal-Wallis 𝐻 test, 𝑃=0.02, Mann-Whitney 𝑈 test: GT+CC versus GT+CT, 𝑃=0.02, GT+CC versus GG+CT, 𝑃=0.014. (b) Number of membrane-bound TNFRI present on CD3⁺ cells in individuals with different genotypes combinations of SNPs TNFRI −609G/T (rs4149569) and TNFRII −3609C/T (rs590368). Kruskal-Wallis 𝐻 test, 𝑃=0.05, Mann-Whitney 𝑈 test: GT+CC versus GT+CT, 𝑃=0.02.

(a)

(b)